Deltex Medical Group PLC Pre-close trading update (5304E)
08 Julio 2021 - 1:00AM
UK Regulatory
TIDMDEMG
RNS Number : 5304E
Deltex Medical Group PLC
08 July 2021
8 July 2021
Deltex Medical Group plc
("Deltex Medical" or the "Group")
Pre-close trading update
Deltex Medical Group plc (AIM: DEMG), the global leader in
oesophageal Doppler monitoring, today publishes an update on
trading for the half-year ended 30 June 2021.
Revenues for the six months ended 30 June 2021 were GBP1.1
million (2020: GBP1.2 million). Unlike 2020, where activity levels
were at pre-pandemic levels in January and February, the whole of
the first half of 2021 has been adversely affected by COVID-19 and
subdued elective surgery activity levels around the world.
The Group's International division saw a signficant increase in
revenues, attributable to Deltex Medical's French distributor
beginning to place regular orders again to satisfy demand
associated with a contract previously awarded by the Greater Paris
University Hospitals (Assistance Publique-Hôpitaux de Paris).
On the basis that the COVID-19 pandemic will abate as the year
progresses, the Group continues to expect revenues to climb in the
second half as the number of elective surgical procedures increases
around the world.
Cash at hand on 30 June 2021 was GBP0.6 million (30 June 2020:
GBP0.6 million).
Nigel Keen, Chairman of Deltex Medical, said:
"Given the subdued state of the Group's core elective surgery
market, combined with ongoing challenges associated with Deltex
Medical's clinical educators visiting key accounts, we are pleased
that overall revenues held up reasonably well in the first
half."
"It is encouraging to see our French distributor starting to
order on a regular basis once more."
"We are looking forward to the elective surgery market starting
to open up around the world in the second half as the benefit of
COVID-19 vaccinations positively affect the prospects for the
Group's core elective surgery markets"
For further information, please contact:
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman investorinfo@Deltexmedical.com
Andy Mears, Chief Executive
Natalie Wettler, Group Finance Director
Arden Partners plc 020 7614 5900
Paul Shackleton info@arden-partners.com
Oscair McGrath
Joint Broker
Turner Pope Investments (TPI) Ltd 0203 657 0050
Andy Thacker info@turnerpope.com
James Pope
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies which are primarily used in critical care and general
surgical procedures. Deltex Medical's proprietary oesophageal
Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow
velocity in the central circulation in real time. Minimally
invasive, easy to set-up and quick to focus, the technology
generates a low-frequency ultrasound signal which is highly
sensitive to changes in blood flow and measures such changes in
'real time'. Deltex Medical is the only company in the enhanced
haemodynamic monitoring space to have built a robust and credible
evidence base demonstrating both the clinical and economic benefits
of its core technology: TrueVue Doppler. This technology has been
proven in a wide range of clinical trials to reduce complications
suffered by patients after surgery and consequently can save
hospitals money.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor
platform now provides clinicians with two further advanced
haemodynamic monitoring technologies. TrueVue Impedance is an
entirely non-invasive monitoring technology which transmits low
magnitude, high frequency electrical signals through the thorax and
measures the changes to this signal when the heart pumps blood.
TrueVue PressureWave uses the peripheral blood pressure signal
analysis to give doctors information on changes in the circulation
and is particularly suited to monitoring lower risk or
haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as a
vital part of the anaesthesia protocols for surgical patients, as
well as treating ventilated intensive care patients, including
ventilated COVID-19 patients. Consequently, the Group's focus is on
maximising value from the opportunities associated with: the CV-19
pandemic; the elective surgery backlog; and the higher profile of
haemodynamic monitoring which has arisen from the recent
consolidation in the sector. The Group aims to provide clinicians
with a modern, next generation, single 'haemodynamic workstation'
platform which offers them a range of technologies from simple to
sophisticated to be deployed according to the patient's clinical
condition as well as the skill and expertise of the user. Doing
this will enable the Group to partner with healthcare providers to
support modern haemodynamic management across the whole
hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK and the USA, and via agreements with approximately 40
distributors overseas.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTDKOBBABKDCOK
(END) Dow Jones Newswires
July 08, 2021 02:00 ET (06:00 GMT)
Deltex Medical (LSE:DEMG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Deltex Medical (LSE:DEMG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024